BIOHIT OYJ STOCK EXCHANGE RELEASE ON 7 MAY 2008 AT 09:50 AM PROLONGATION OF THE FDA APPROVAL PROCEDURE FOR BIOHIT'S GASTROPANEL TESTS The US Food and Drug Administration (FDA) has demanded further clarifications regarding the clearance application for the Pepsinogen I and II tests included in the GastroPanel examination. Authorisation was previously expected before the end of the first half of 2008 but due to the new request the procedure will be prolonged. At this stage it is therefore difficult to estimate the schedule for the whole approval procedure. We will inform about the case later, as we get further information from FDA. Osmo Suovaniemi President & CEO Biohit Oyj Further information: Osmo Suovaniemi, M.D., Ph.D., Professor President & CEO Tel: +358-9-773 861 GSM: +358-40-745 5605 Email: osmo.suovaniemi@biohit.com Distribution: Helsinki Exchanges Central storage facility Press www.biohit.com